• Publications
  • Influence
A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus
We have identified a major T-cell epitope, amino acids 48-54 (DRAHYNI, in one-letter code) in the E7 open reading frame protein of human papillomavirus (HPV) type 16. Lymph node cells from miceExpand
Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin.
  • X. Chen, T. Prow, +5 authors M. Kendall
  • Chemistry, Medicine
  • Journal of controlled release : official journal…
  • 3 November 2009
Dry-coated microprojections (MPs) deliver vaccine to abundant immunogenic cells within the skin to induce immune responses. Success in this targeted vaccine delivery relies on overcoming theExpand
The vaccinia virus K2L gene encodes a serine protease inhibitor which inhibits cell-cell fusion.
In certain circumstances, cells infected with vaccinia virus (VV) undergo fusion, but this does not occur in tissue cultures infected with wild-type VV. The VV genome includes three genes (B24R,Expand
Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination.
Development of CD8 alphabeta CTL epitope-based vaccines requires an effective strategy capable of co-delivering large numbers of CTL epitopes. Here we describe a DNA plasmid encoding a polyepitope orExpand
Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway.
To evaluate an antigen delivery system in which exogenous antigen can target the major histocompatibility complex (MHC) class I pathway, a single human papillomavirus (HPV) 16 E7 cytotoxic TExpand
Potent Immunity to Low Doses of Influenza Vaccine by Probabilistic Guided Micro-Targeted Skin Delivery in a Mouse Model
Background Over 14 million people die each year from infectious diseases despite extensive vaccine use [1]. The needle and syringe—first invented in 1853—is still the primary delivery device,Expand
Nanopatch targeted delivery of both antigen and adjuvant to skin synergistically drives enhanced antibody responses.
Many vaccines make use of an adjuvant to achieve stronger immune responses. Alternatively, potent immune responses have also been generated by replacing the standard needle and syringe (which placesExpand
ISCOMATRIX adjuvant: an adjuvant suitable for use in anticancer vaccines.
Human Papillomavirus type 16 (HPV16) E6 and E7 oncoproteins are associated with cervical cancer development and progression and can therefore be used as target antigens for cancer immunotherapy. InExpand
Antigen-specific CD4+ T-cell help is required to activate a memory CD8+ T cell to a fully functional tumor killer cell.
Although the importance of CD4+ T-cell help for generation of an effective CD8+ effector cytotoxic T cell (CTL) response is well established, the role of T-cell help in the activation of memory TExpand
Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
Many cervical cancers express the E7 protein of human papillomavirus 16 as a tumor-specific Ag (TSA). To establish the role of E7-specific T cell help in CD8+ CTL-mediated tumor regression, C57BL/6JExpand